Skip to main content

Research at Alzheimer Society of Canada

1-855-705-4636
  • Find a Research Study
  • FAQs
  • Legal Disclaimer
  • Contact Us
  • Français

Alzheimer Society of Canada

Find a Research Study

A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline

What is this Study about?

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.

Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

What Will Happen in This Study?

Participant will take the study drug by subcutaneous injection.  
Planned duration of treatment is 255 weeks.

Who is Eligible to Participate in this Study?

Male or female participants aged 65 to 80 years of age 
Minimal to no cognitive/functional impairment at Screening
Must have a study partner

Get in Touch About this Study

Legal Disclaimer

Any materials or links provided herein are strictly for informational purposes only. The Alzheimer Society of Canada does not endorse nor recommend any of the manufacturers, products or institutions mentioned in any of these links or listings as suitable or appropriate for your particular situation or circumstances and disclaims any liability with respect to representations, warranties, including fitness for an intended particular use or purpose, and all other claims relating thereto, all of which remain strictly with the manufacturer or institution.

In no event shall the Alzheimer Society of Canada or any third parties mentioned on the website be liable for any damage (including, without limitation, incidental and consequential damages for personal injury/wrongful death, lost profits or damages resulting from lost data or business interruption) or personal injury (including death) resulting from the use, misuse or inability to use any activity, product or service mentioned herein, whether based in warranty, contract, tort or any other legal theory.

Everyone considering participating in any activity is encouraged to speak with their own doctor or health-care team before participating in any activity that may impact their health or well-being.

Clinical Trial

Target Population

Person at risk of Alzheimer's disease (AD) or living with pre-clinical AD

Target Age Group(s)

66+

Study Location

In-Person

Ontario: Baycrest, Kawartha, Sunnybrook

British Columbia: Medical Arts West Vancouver

British Columbia, Ontario

Recruitment Start Date

April 7, 2025

Recruitment End Date

April 1, 2029
  • Learn more about observational studies
  • Learn more about clinical trials
  • Brain donations
  • More useful links and resources

Alzheimer Society of Canada logo

Alzheimer Society of Canada
20 Eglinton Avenue West, 16th Floor
Toronto, Ontario M4R 1K8
Information and Referral Line: 1-855-705-4636
Email: research@alzheimer.ca

Charity registration number: 11878 4925 RR0001

Follow us:

  • Find us on Facebook
  • Follow us on Twitter
  • Follow us on Instagram
  • Subscribe to us on YouTube
  • Find us in LinkedIn

©2022 Alzheimer Society of Canada. All rights reserved.